BIM-IOL System

Open-angle glaucoma or ocular hypertension

Manufacturer: SpyGlass Pharma
Regulatory submission: NDA planned for 2028
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description

Product information

80 evidence topics · 18 sources

Generic, brand name and therapeutic class of product3 evidence topics · 2 sources
Dosage forms and strengths6 evidence topics · 3 sources
Average sales price and wholesale acquisition cost2 evidence topics · 2 sources
American hospital formulary service (AHFS), or other drug classification2 evidence topics · 2 sources
Indication2 evidence topics · 3 sources
Pharmacology14 evidence topics · 5 sources
Contraindications/Warnings/Precautions/Adverse effects6 evidence topics · 4 sources
Special populations7 evidence topics · 5 sources
Drug/Drug, drug/disease interactions3 evidence topics · 2 sources
Dosing and administration9 evidence topics · 6 sources
Access and distribution6 evidence topics · 2 sources
Co-prescribed/Concomitant therapies6 evidence topics · 5 sources
Effect of BIM-IOL System on quality measures5 evidence topics · 5 sources
Product comparison9 evidence topics · 7 sources